1. Market Research
  2. > Pharmaceutical
  3. > Prescription Drug Market Trends
Company Profile: Novo Nordisk

Company Profile: Novo Nordisk

  • December 2017
  • 36 pages
  • ID: 5336386
  • Format: PDF
  • By Datamonitor Healthcare

Summary

Table of Contents

Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Amgen’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

Snapshot
Overview – Novo Nordisk continues to dominate the diabetes segment, with approvals of the next-generation insulin FIAsp (ultra fast-acting insulin aspart) and the GLP-1 agonist Ozempic (semaglutide) set to further boost sales.
Out to 2021 – Novo Nordisk will experience headwinds, especially in the US, as pricing pressure results in steadily declining diabetes sales.
Out to 2026 – Novo Nordisk is likely to look for alternative therapy segments to source long-term growth as the diabetes market becomes increasingly crowded.
Pipeline – The highly anticipated oral semaglutide is in Phase III trials, while hemophilia treatment N8-GP is set for approval in 2018.
Events – Novo Nordisk gained US Food and Drug Administration approval for GLP-1 agonist Ozempic in December 2017, with product launch expected on 1 January 2017.

Highlights
Q3 2017: Novo Nordisk’s Q3 2017 sales are up by 2%.
Despite headwinds in the US diabetes market, Novo Nordisk will continue to dominate the global metabolic market.
Novo Nordisk’s hematology segment will contribute a comparatively modest proportion of total sales, despite approval of new medicines over the forecast period.

Model updates
N9-GP updated to Rebinyn.
Oral semaglutide (NN9924) added.
Saxenda added.
Semaglutide changed to Ozempic.

Analysis structure
Explore and visualize revenue dynamics in Amgen’s portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context
How is Novo Nordisk strategically poised out to 2026?
What are Novo Nordisk’s key strengths, weaknesses, opportunities, and threats?
What are Novo Nordisk’s key catalysts during the current year?

Facts and figures
What is Novo Nordisk’s forecasted sales performance out to 2026?
What is the revenue trajectory of Novo Nordisk’s current top 10 products out to 2026?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Novo Nordisk based on the lifecycle of its products?

Key therapy areas
Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in Novo Nordisk’s important therapeutic markets?
How is Novo Nordisk adapting strategically to internal and external headwinds?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019

  • $ 2000
  • September 2019

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H2 2019, provides an overview ...

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral ...

Diabetic Nephropathy - Pipeline Review, H2 2019

Diabetic Nephropathy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Diabetic Nephropathy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic ...

Incretion Drugs Markets in China $ 4000 October 2019


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on